Literature DB >> 15193411

Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins.

C B Palatnik de Sousa1, W R Santos, C P Casas, E Paraguai de Souza, L W Tinoco, B P da Silva, M Palatnik, J P Parente.   

Abstract

The presence of aldehyde groups at C-23 and C-24 of the triterpen aglycon moiety was disclosed in 1H NMR spectra of both the Riedel de Haen saponin (R) (delta 9.336) and Quillaja saponaria QuilA saponin (delta 9.348). The sign of the C-28 acylated linked moiety (delta 176) was present in both saponins, while the delta 171 at C-28 (carboxy group) corresponding to the deacylated saponin, was only detected in the QuilA preparation, indicating 50% of hydrolysis of the ester moiety, probably due to the storage in aqueous solution. The normoterpen moiety was present in both saponins (signals at delta 14-18). The chemical removal of saponin glicidic moieties gave rise to their sapogenin fractions. Their 1H NMR spectra showed the presence of two signals (delta 9.226 and 9.236) for sapogenin R and two signals (delta 9.338 and 9.352) for the QuilA sapogenin. The intensity of the signals suggested two conformational isomers of sapogenin R in the ratio 53% of equatorial aldehyde group to 47% of axial aldehyde group, and two conformational isomers of QuilA sapogenin in the ratio 76% of equatorial aldehyde group to 24% of axial aldehyde group. The chemical treatment abolished the saponin slight in vivo toxicity, reduced their hemolytic potential, did not affect their aldehyde contents, but gave rise to an enriched axial aldehyde-containing sapogenin R with enhanced potential on antibody humoral response (anti-IgM, IgG, IgG1, IgG2a, IgG2b and IgG3) and to an enriched equatorial aldehyde-containing QuilA-sapogenin that induced a mainly cellular specific immune response (increased intradermal response to leishmanial antigen and IFNgamma sera levels) and effective protection against murine infection by L. donovani (77% reduction in liver parasitic load). Our results suggest that the Riedel de Haen saponin is probably a Quillaja saponaria saponin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193411     DOI: 10.1016/j.vaccine.2004.01.072

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Protective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice.

Authors:  Sandra R Afonso-Cardoso; Flavio H Rodrigues; Marcio A B Gomes; Adriano G Silva; Ademir Rocha; Aparecida H B Guimaraes; Ignes Candeloro; Silvio Favoreto; Marcelo S Ferreira; Maria A de Souza
Journal:  Korean J Parasitol       Date:  2007-12       Impact factor: 1.341

Review 2.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

3.  Yucca schidigera can mitigate ammonia emissions from manure and promote poultry health and production.

Authors:  Muhammad Saeed; Muhammad Asif Arain; Muhammad Naveed; Mahmoud Alagawany; Mohamed Ezzat Abd El-Hack; Zohaib Ahmed Bhutto; Marek Bednarczyk; Mohib Ullah Kakar; Mervat Abdel-Latif; Sun Chao
Journal:  Environ Sci Pollut Res Int       Date:  2018-10-27       Impact factor: 4.223

4.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

5.  Association between haptoglobin and IgM levels and the clinical progression of caseous lymphadenitis in sheep.

Authors:  Bruno L Bastos; Dan Loureiro; José T Raynal; Maria T Guedes; Vera Lúcia Costa Vale; Lilia F Moura-Costa; José E Guimarães; Vasco Azevedo; Ricardo W Portela; Roberto Meyer
Journal:  BMC Vet Res       Date:  2013-12-13       Impact factor: 2.741

6.  Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine.

Authors:  F N Santos; G P Borja-Cabrera; L M Miyashiro; J Grechi; A B Reis; M A B Moreira; O A Martins Filho; M C R Luvizotto; I Menz; L M Pessôa; P R Gonçalves; M Palatnik; C B Palatnik-de-Sousa
Journal:  Vaccine       Date:  2007-06-21       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.